Legg Mason ClearBridge's Vitrano: Why Uber has turned a corner

Ride-sharing app fortunes turn for the better

James Baxter-Derrington
clock • 3 min read

"The Uber that went public was a new Uber," according to co-manager of the £1.2bn Legg Mason ClearBridge US Large Cap Growth fund Margaret Vitrano, who bought shares in the company when it first floated onto the New York Stock Exchange last year.

When the ride-hailing app's company went public in May 2019, there was a "disconnect between perception and reality" due to "a period of missteps and bad publicity in multiple markets", which made it a contrarian pick, said Vitrano. Less than one month after the flotation - in which the stock tumbled during early trading - the taxi firm posted a $1bn (£790m) quarterly loss, leading to an 11% share price fall within its first 20 days. But while Uber's share price continued to struggle over the next six months, having fallen in value by more than 35%, Vitrano said its share price has no...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot